LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced today that it has initiated a strategic evaluation process with Vertice Seguros, a Venezuelan insurance provider, to explore integrating insurance products with its digital healthcare ecosystem.
The evaluation aims to assess a framework where life and health insurance products from Vertice Seguros could become accessible through LataMed AI's platforms, while Vertice Seguros clients could access LataMed AI's telehealth, care coordination, analytics, and AI-enabled solutions. This proposed collaboration could create complementary opportunities by expanding customer reach and increasing healthcare accessibility, especially in underserved markets.
Preliminary operational, technical, and commercial evaluations are underway to assess user onboarding, platform integration, workflows, regulatory considerations, and commercialization potential. These activities will determine the feasibility of a broader strategic relationship.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated, 'Our vision is to create a more connected healthcare ecosystem where technology, care delivery, and financial protection solutions work together to improve accessibility and outcomes. We believe this evaluation process with Vertice Seguros represents an opportunity to explore how healthcare technology services and insurance solutions can be combined within a unified digital platform.'
The proposed evaluation aligns with LataMed AI's strategy of developing an integrated healthcare ecosystem combining artificial intelligence, telehealth infrastructure, analytics, care coordination, pharmacy connectivity, and emergency response capabilities, initially focused on Latin America. The company believes that combining healthcare technology with insurance accessibility can support greater patient engagement and improve long-term outcomes.
Any definitive arrangement remains subject to successful completion of the evaluation, negotiation of final terms, regulatory considerations, and execution of definitive agreements. The company will provide updates as material developments occur. For additional information, visit https://latamed.ai or review SEC filings at www.sec.gov.
